In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Analgesic; opioid'
Please login to view adverse reactions.
- (2015): Benson JL+, Consult Pharm 30(4), 221
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2023): Sherbini AE+, Trends Cardiovasc Med Apr, Online ahead of print [REVIEW]
- (2022): Hahn J+, Front Pharmacol Oct (e-Collection) [REVIEW] (with gabapentinoid co-administration)
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6326%
- (2022): Raso J+, Int J Clin Pharm Jan, Online ahead of print (association)
Encephalopathy (includes hepatic encephalopathy)
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2016): Sivanesan E+, Anesth Analg 123(4), 836 [REVIEW]
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2015): Zadori D+, Expert Opin Drug Saf 14(6), 877 [REVIEW]
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2021): Tanaka R+, Medicine (Baltimore) 100(44), e27565 (genotype correlation)
Endocrine-related adverse effect / endocrinopathy
- (2021): Medina II WA+, Jul [REVIEW]
Hypogonadism (includes androgen deficiency)
- (2025): Kafel H+, Andrology Feb, Online ahead of print [REVIEW]
- (2025): Boilève A+, Bull Cancer (French) Feb, Online ahead of print [REVIEW]
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2022): Alvaro D+, Pain Ther Feb, Online ahead of print [REVIEW]
- (2018): Bhimji SS+, StatPearls Mar, Epub
- (2016): Soleimanpour H+, Hepat Mon 16(4), Epub [REVIEW]
- (2015): Nelson AD+, Therap Adv Gastroenterol 8(4), 206 [REVIEW]
- (2015): Sani H+, Consult Pharm 30(10), 61280%
- (2024): Kang Y+, Int J Mol Sci 25(16), 8845 (pharmacogenomics)
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2023): Hiratsuka Y+, Support Care Cancer 31(12), 6325%
- (2023): Lakkad M+, J Cancer Surviv Feb, Online ahead of print (with gabapentinoid)
Adverse effects / adverse reactions
- (2021): Omoto T+, Biol Pharm Bull 44(5), 627-634 [REVIEW]
- (2021): Paul AK+, Pharmaceuticals (Basel) 14(11), 1091 [REVIEW]
- (2014): Carter GT+, Phys Med Rehabil Clin N Am 25(2), 457 [REVIEW]
